可切除胃癌患者的围手术期化疗与术后辅助化疗的比较：一项带有荟萃分析的系统回顾。
Perioperative Chemotherapy versus Adjuvant Chemotherapy in Patients with Resectable Gastric Cancer: A Systematic Review with meta-analysis.
发表日期：2023 Jul 31
作者：
Chenyu Wei, Xuelin Du, Jiexuan Hu, Yin Dong, Yan Chen, Bangwei Cao
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
本研究旨在比较围手术期化疗（PC）与辅助化疗（AC）在预后和安全性方面的差异。我们系统性地搜索和评估了PubMed、Embase和Cochrane图书馆中自始至2022年9月1日的研究。共有18项符合分析条件的研究，涵盖了4686名患者。我们的研究发现，相较于接受AC的患者，接受PC的可切除胃癌患者在总生存期（HR 0.77；95% CI 0.69至0.87）和无病生存期（HR 0.76；95% CI 0.69至0.84）上有较好的预后。将新辅助化疗（NAC）与AC结合使用可以提高R0切除率，但不会增加术后并发症风险和大多数不良事件发生率。我们的研究证明，在可切除胃癌的亚洲患者中，与AC相比，PC在总生存期和无病生存期方面效果更好。考虑到其良好的预后和类似的安全性，应优先选择PC。版权所有©2023。Elsevier B.V.出版。
The study aimed to investigate the prognosis and safety of perioperative chemotherapy (PC) compared with adjuvant chemotherapy (AC).We systematically searched and assessed studies in PubMed, Embase, and the Cochrane Library from inception to 1st September 2022.Eighteen studies were eligible for the analysis, including 4686 patients in total. Our study found that patients with resectable gastric cancer undergoing PC had favorable prognosis on OS (HR 0.77; 95% CI 0.69 to 0.87) and DFS (HR 0.76; 95% CI 0.69 to 0.84) than those who undergoing AC. Addition of neoadjuvant chemotherapy (NAC) to AC provided higher R0 resection rate but did not increase the risk of postoperative complication rate and most of the adverse event rates.Our study demonstrated that PC shows better OS and DFS in Asians with resectable gastric cancer compared with AC. PC should be preferred because of its favorable prognosis and similar safety.Copyright © 2023. Published by Elsevier B.V.